期刊
STEM CELLS
卷 39, 期 1, 页码 26-32出版社
OXFORD UNIV PRESS
DOI: 10.1002/stem.3278
关键词
engraftment; exosomes; extracellular vesicles; graft failure; hematopoietic stem cell transplantation; hematopoietic stem cells; mesenchymal stromal cells; microvesicles; poor graft function
资金
- Consejeria de Educacion, Junta de Castilla y Leon [CAS079P17, HUS308U14]
- Consejeria de Sanidad de Castilla y Leon [GRS1348/A/19, GRS1621/A/17, GRS1879/A/18]
- Fundacion Espanola de Hematologia y Hemoterapia
- Instituto de Salud Carlos III [PI12/01775, PI16/01407]
- ISCIII-European Regional Development Fund [RD16/0011/0015]
This review summarizes the potential of mesenchymal stromal cells to improve hematopoietic function through the secretion of extracellular vesicles after allogenic hematopoietic stem cell transplantation. It also discusses the advantages of EVs over MSCs, as well as the challenges and uncertainties that need to be addressed for their clinical application.
The therapeutic effects of mesenchymal stromal cells (MSCs) in graft failure or poor graft function after allogenic hematopoietic stem cell transplantation (HSCT) are currently undergoing clinical evaluation. MSCs exert their functions, at least partially, through the secretion of extracellular vesicles (MSC-EVs). The available information on the biological potential of MSC-EVs to improve hematopoietic function, both in in vitro studies and in reported preclinical models, focusing on the possible mechanisms of these effects are summarized in the current review. The potential advantages of EVs over MSCs are also discussed, as well as the limitations and uncertainties in terms of isolation, characterization, mechanism of action in this setting, and industrial scalability that should be addressed for their potential clinical application.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据